Biointaxis Sl

Biointaxis creates significant value at the early stages of product development (R&D), Pre-clinical (proof-of-concept and regulatory) and early clinical trials (Phase I/II). We aim to license the production and distribution rights to Pharma partners equipped with a reputation. Biointaxis is an academic spin-off company benefiting from extensive know-how in the identification of genes and mechanisms underlying neurodegenerative disorders. As shown in the table below our the leading candidate is a gene therapy product for the treatment of Friedreich Ataxia. We are currently developing a gene therapy treatment for Friedreich´s ataxia, a rare inherited, progressive, neurodegenerative disease that typically affects teenagers and young adults.  Our research shows efficacy of the treatment being able to re-establish the neurological functions in mice models of Friedreich´s ataxia.